In VivoBiopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu
ScripTwo more small biopharmaceutical companies managed to launch initial public offerings recently, bringing the 2022 total to 17 drug developers that have gone public in the US this year, despite the fac